Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwAL 2018

AML

View all
3:01
T-cell engaging antibodies: novel combinations to overcome resistance
Marion Subklewe • 17 Feb 2018
5:10
Future frontiers in AML: the five key therapy pillars & the future of trials
Naval Daver • 17 Feb 2018

ALL

View all
3:35
The role of MRD in ALL: what defines a complete response?
Bijal Shah • 17 Feb 2018
1:10
Target antigens for T-cell engager therapies in ALL and AML
Marion Subklewe • 17 Feb 2018

Panel Discussions

View all
6:42
MRD for acute leukemias: opinion from both sides of the Atlantic
Alan Burnett et al. • 17 Feb 2018
7:40
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
John DiPersio et al. • 17 Feb 2018

Expert Interviews

View all
2:41
Lifting limits: liposomal delivery of chemotherapy for secondary AML with CPX-351
Jeffrey Lancet • 17 Feb 2018
5:15
Smoothening the spines: hedgehog signaling inhibitor glasdegib combinations for AML
Jorge Cortes • 5 Mar 2018
The content of VJHemOnc is intended for healthcare professionals